Chordoma Foundation


General Characteristics

Age: 57 years
Gender: Female
Disease Origin: Sacral
Disease Status: Recurrent
Source: Beate Rinner and Bernadette Liegl
Medical University of Graz


Molecular Features

Cell morphology: Physaliferous
T expression: Positive; 10x that of U-CH2 and with T amplification
T localization: Nuclear
CD24 expression: Positive; 4.33x that of U-CH2
HLA Type: A11
Chromosomal abnormalities: Multiple, including gain at 6q27 (T locus), loss at 9p (CDKN2A and CDKN2B loci), loss at 10p and 10q (PTEN and PDCD4 loci)
Sequence data:  WGS and Transcriptome data available contact
Validation results: Validation Report


Growth Conditions

Growth medium: IMDM: RPMI-1640 (4:1) +10% FBS
Freeze medium: 70% complete growth medium supplemented with an additional 20% fetal bovine serum and 10% DMSO
Culture conditions: Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing instructions: Cell Culture Procedures



Characterized By:

  • Rinner B, Froehlich EV, Buerger K, Knausz H, Lohberger B et al. (2012) Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. Int J Oncol 40(2):443-51.  PubMed: 22002331.

Additional References:

  • Scheipl S, Lohberger B, Rinner B, Froehlich EV, Beham A, Quehenberger F et al. Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: an immunohistochemical and functional analysis. J Orthop Res 31(12):1999-2005. PubMed: 23893747.

Pin It on Pinterest

Share This
Comodo SSL